{"id":852699,"date":"2025-05-20T08:04:48","date_gmt":"2025-05-20T12:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/"},"modified":"2025-05-20T08:04:48","modified_gmt":"2025-05-20T12:04:48","slug":"atyr-pharma-to-present-at-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/","title":{"rendered":"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, May  20, 2025  (GLOBE NEWSWIRE) &#8212; aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025.<\/p>\n<p align=\"justify\">Details of the conferences appear below:<\/p>\n<p>Conference: RBC Capital Markets Global Healthcare Conference<br \/>Date: Wednesday, May 21, 2025<br \/>Time: 11:00am EDT<br \/>Location: New York, NY<br \/>Format: Fireside Chat<\/p>\n<p>Conference: Piper Sandler 3<sup>rd<\/sup> Annual Virtual Lung Symposium with ATS Takeaways<br \/>Date: Tuesday, May 27, 2025<br \/>Time: 2:00pm EDT<br \/>Location: Virtual<br \/>Format: Fireside Chat<\/p>\n<p>Conference: Jefferies Global Healthcare Conference<br \/>Date: Thursday, June 5, 2025<br \/>Time: 2:00pm EDT<br \/>Location: New York, NY<br \/>Format: Fireside Chat<\/p>\n<p align=\"justify\">In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor\u2019s section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GS07k1QlKa5CsfMJMkDB4TgxNYJIg7ag_hMY3OAuDu_mfaS1MK8dWXPWEZFFIHDc70N01Ps_bjs1U9fsoF7irkjAlIJLaVR-l1-dadbQEFI=\" rel=\"nofollow\" target=\"_blank\">www.atyrpharma.com<\/a>. Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AVxQULoWmKytq30EzXdqt2fK93sI2NA3EcMzdfH0fLAW5HoKtIkQmwrZAqtytqgryC444uSnLFliDWOjVacMyb2WuUIm_IZ-BV96inM9BaFDByoTRnT-yVkPRjtc2qBvPAj9fSzjXdN1cZrJVbb3Sg==\" rel=\"nofollow\" target=\"_blank\">investorrelations@atyrpharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Abo<\/strong><br \/>\n        <strong>ut aTyr<\/strong>\n      <\/p>\n<p align=\"justify\">aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr\u2019s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr\u2019s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GS07k1QlKa5CsfMJMkDB4T53AbX7EgMRNFptVu7n4B-BO2kByQh8GLj96oFvZw4jyu7RUmJYaV_BOVNKtNnwFvkSCLdbE_MWa6okLYxz_Ck=\" rel=\"nofollow\" target=\"_blank\">www.atyrpharma.com<\/a>.<\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Contact:<\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Ashlee Dunston<\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Sr. Director, Investor Relations and Public Affairs<\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:adunston@atyrpharma.com\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <u>adunston@atyrpharma.com<\/u><br \/>\n            <\/a>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: top\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmQ3ZTAxNmItMDExNi00MDg4LWFhOWMtYjU5NjlmZWM3NzhhLTEwMjkxNDItMjAyNS0wNS0yMC1lbg==\/tiny\/aTyr-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) &#8212; aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 11:00am EDTLocation: New York, NYFormat: Fireside Chat Conference: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS TakeawaysDate: Tuesday, May 27, 2025Time: 2:00pm EDTLocation: VirtualFormat: Fireside Chat Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 2:00pm EDTLocation: New York, NYFormat: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8221;\u00a0aTyr Pharma to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-852699","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00a0aTyr Pharma to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) &#8212; aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 11:00am EDTLocation: New York, NYFormat: Fireside Chat Conference: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS TakeawaysDate: Tuesday, May 27, 2025Time: 2:00pm EDTLocation: VirtualFormat: Fireside Chat Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 2:00pm EDTLocation: New York, NYFormat: &hellip; Continue reading &quot;\u00a0aTyr Pharma to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences\",\"datePublished\":\"2025-05-20T12:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/\"},\"wordCount\":337,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/\",\"name\":\"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=\",\"datePublished\":\"2025-05-20T12:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) &#8212; aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 11:00am EDTLocation: New York, NYFormat: Fireside Chat Conference: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS TakeawaysDate: Tuesday, May 27, 2025Time: 2:00pm EDTLocation: VirtualFormat: Fireside Chat Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 2:00pm EDTLocation: New York, NYFormat: &hellip; Continue reading \"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-20T12:04:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences","datePublished":"2025-05-20T12:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/"},"wordCount":337,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/","name":"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=","datePublished":"2025-05-20T12:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NDU5NiM2OTUwNTMxIzIwMTc1Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atyr-pharma-to-present-at-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"\u00a0aTyr Pharma to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=852699"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852699\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=852699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=852699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=852699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}